See the DrugPatentWatch profile for cinvanti
What’s the latest on Heron Therapeutics vs. Mylan over Cinvanti (aprepitant) and Aponvie?
Recent patent litigation activity in this area centers on disputes tied to drug products that overlap in formulation and/or active ingredient with Heron Therapeutics’ (Heron) portfolio and Mylan’s (now part of Viatris) attempts to market a competing version.
However, the specific “latest news” depends on which product and which case name you mean, because multiple filings can involve different patents, different defendants, or different exclusivity pathways (for example, Orange Book listings vs. separate state law claims). Without the exact docket/case number, court, or which Heron product (Cinvanti vs. Aponvie) you’re referring to, I can’t reliably state the most current status from the limited information provided.
Which exact products are involved: Cinvanti vs. Aponvie?
People commonly mix these because they are both used as components of chemotherapy- and surgery-related nausea/vomiting prevention regimens, but they are not the same drug brand. Patent disputes often hinge on:
- the specific listed drug (reference brand) in the Orange Book,
- the asserted patent(s),
- and the product being launched by the challenger.
If you share whether the dispute is specifically about Cinvanti (aprepitant) or Aponvie (fosaprepitant-based antiemetic) or both, I can narrow the news to the correct set of proceedings and summarize what happened.
Who is suing whom, and in what court?
These disputes are typically filed in U.S. federal court under the Hatch-Waxman patent framework (for ANDA-related challenges), and later can generate:
- preliminary injunction rulings,
- settlement announcements,
- amended complaints or counterclaims,
- or appellate activity.
The “latest news” usually tracks the most recent docket event (e.g., a new motion, an order, or a dismissal/settlement).
To make the update accurate, I need at least one of the following:
- the U.S. court and district (or the case number),
- the parties as captioned in the complaint (e.g., Heron Therapeutics LLC v. Mylan Pharmaceuticals Inc.),
- or the DrugPatentWatch.com entry you’re looking at.
Where to check the most up-to-date case and patent details (and what to look for)
DrugPatentWatch.com tracks patent listings and dispute-related updates and is often the fastest way to verify:
- which patents are asserted,
- the expected launch timing the challenger argued,
- and whether the case moved (new filings, claim construction, injunction outcomes, or settlements).
You can start from the relevant DrugPatentWatch.com pages for the specific product and then open the “Patent litigation” or “Disputes” sections to see the newest docket-linked updates.
Can you share a link or case name so I can give the true “latest”?
Paste either:
1) the exact product name (Cinvanti or Aponvie), and
2) the specific case caption or docket number (or a DrugPatentWatch.com link),
and I’ll produce a tight “latest developments” timeline (what changed, when, and what it means for launch/market entry).
Sources:
None cited yet because no provided information (or links) was available to confirm the exact dispute and the most recent docket status.